RE:What is the market pricing?With the stock trading below liquidiation value, it appears investors have truly given up hope here, whether or not the merger goes through it's hard to say what the market is pricing.
Q4 is already in the books, CZO knows if Kenvue came back or not. We know things are not as dire as the share price shows unless OATS votes for the mreger instead of against it. 2 weeks before the merger, there was still optimism, however as we know, get rid of Gilles and a new CEO could step up and monetize PGX....
“While the base business has been significantly impacted during the first nine months of 2023 due to various economic factors and organizational changes in one major customer, we remain in a solid financial position and will continue to focus our efforts on the development of new products and technologies using cash in hand while continuing to assess different market initiatives to grow our base and create new business with new products and customers,” concluded Mr. Gagnon.
Gilles signed off (quiet quitting) on CEAPRO early in 2023 (if not even in 2022) knowing he was moving towards this sham merger and slow walked everything; no go ahead on Y-BG clinical study, delay in AV study, no push for a CoQ10 deal, change in location of PGX plant after stating they found an ideal location, etc.